HCW Biologics Inc. (HCWB) Insider Trading Activity

NASDAQ$0.6011-0.01 (-1.64%)
Market Cap
$1.31M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
88 of 885
Rank in Industry
65 of 507

HCWB Insider Trading Activity

HCWB Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$3,045,056
9
100
Sells
$0
0
0

Related Transactions

Wong Hing CChief Executive Officer
2
$2.47M
0
$0
$2.47M
GARRETT SCOTT Tdirector
2
$240,011
0
$0
$240,011
Byam RebeccaChief Financial Officer
1
$220,012
0
$0
$220,012
Winer Gary Mdirector
2
$70,006
0
$0
$70,006
Flowers LeeSVP of Business Development
1
$25,012
0
$0
$25,012
Greene Rick S.director
1
$25,012
0
$0
$25,012

About HCW Biologics Inc.

HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

Insider Activity of HCW Biologics Inc.

Over the last 12 months, insiders at HCW Biologics Inc. have bought $3.05M and sold $0 worth of HCW Biologics Inc. stock.

On average, over the past 5 years, insiders at HCW Biologics Inc. have bought $2.99M and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Wong Hing C (Chief Executive Officer) — $2.47M. GARRETT SCOTT T (director) — $240,011. Byam Rebecca (Chief Financial Officer) — $220,012.

The last purchase of 8,054 shares for transaction amount of $60,002 was made by Wong Hing C (Chief Executive Officer) on 2025‑05‑16.

List of Insider Buy and Sell Transactions, HCW Biologics Inc.

2025-05-16PurchaseWong Hing CChief Executive Officer
8,054
0.4658%
$7.45
$60,002
-55.81%
2025-05-16PurchaseGARRETT SCOTT Tdirector
13,423
0.7763%
$7.45
$100,001
-55.81%
2025-05-16PurchaseWiner Gary Mdirector
1,342
0.0776%
$7.45
$9,998
-55.81%
2025-05-08PurchaseWong Hing CChief Executive Officer
92,500
29.9424%
$26.00
$2.4M
-43.99%
2025-05-08PurchaseByam RebeccaChief Financial Officer
8,462
2.7392%
$26.00
$220,012
-43.99%
2025-05-08PurchaseGARRETT SCOTT Tdirector
5,385
1.7431%
$26.00
$140,010
-43.99%
2025-05-08PurchaseFlowers LeeSVP of Business Development
962
0.3114%
$26.00
$25,012
-43.99%
2025-05-08PurchaseWiner Gary Mdirector
2,308
0.7471%
$26.00
$60,008
-43.99%
2025-05-08PurchaseGreene Rick S.director
962
0.3114%
$26.00
$25,012
-43.99%
2023-09-14PurchaseWong Hing CChief Executive Officer
1,800
0.0049%
$2.08
$3,741
-46.48%
2023-09-14PurchaseWiner Gary Mdirector
1,041
0.0028%
$2.05
$2,139
-46.48%
2023-09-13PurchaseByam RebeccaChief Financial Officer
5,000
0.0144%
$2.10
$10,490
-43.32%
2023-09-13PurchaseWiner Gary Mdirector
546
0.0015%
$2.05
$1,117
-43.32%
2023-09-12PurchaseByam RebeccaChief Financial Officer
5,000
0.0143%
$2.09
$10,442
-43.35%
2023-09-12PurchaseWiner Gary Mdirector
500
0.0014%
$2.05
$1,025
-43.35%
2023-09-11PurchaseByam RebeccaChief Financial Officer
5,000
0.0145%
$2.05
$10,273
-41.62%
2023-09-11PurchaseWiner Gary Mdirector
99
0.0003%
$2.05
$203
-41.62%
2023-09-08PurchaseByam RebeccaChief Financial Officer
5,000
0.0137%
$2.02
$10,111
-43.90%
2023-09-08PurchaseWiner Gary Mdirector
1
<0.0001%
$1.90
$2
-43.90%
2023-09-07PurchaseByam RebeccaChief Financial Officer
5,000
0.0139%
$1.95
$9,742
-41.03%
Total: 66
*Gray background shows transactions not older than one year

Insider Historical Profitability

<0.0001%
Wong Hing CChief Executive Officer
501911
23.3273%
$306,165.71160
<0.0001%
Byam RebeccaChief Financial Officer
43010
1.999%
$26,236.10230
<0.0001%
GARRETT SCOTT Tdirector
25505
1.1854%
$15,558.0530
<0.0001%
Flowers LeeSVP of Business Development
5720
0.2658%
$3,489.2060
<0.0001%
Winer Gary Mdirector
4075
0.1894%
$2,485.75130
Greene Rick S.director
2066
0.096%
$1,260.2630
<0.0001%
Rhode PeterSee Remarks
46785
2.1744%
$28,538.8510
<0.0001%
Jiao Jin-anVP of Development
30571
1.4208%
$18,648.3110
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$1,848,072
66
-14.67%
$2.37M
$1,138,733
28
-4.94%
$3.39M
HCW Biologics Inc.
(HCWB)
$8,079,884
14
-43.20%
$1.31M
$105,917
11
-28.06%
$2.28M
$82,890
11
-16.74%
$1.6M
$18,269
10
-21.15%
$2.41M
$126,023
10
-66.17%
$2.59M
$90,087
9
20.06%
$2.17M
$7,268,979
7
-48.44%
$2.59M
$245,000
7
-62.00%
$3.12M
$70,828
6
-57.96%
$1.54M
$553,551
4
-74.30%
$477,533.00
$149,778
4
-45.16%
$3.17M
$726,438
4
-72.85%
$1.03M
$37,000
1
79.42%
$2.62M
$23,454
1
-99.16%
$13,049.00
$19,863
1
144.27%
$1.14M
$9,963
1
-14.25%
$2.4M
$1,049,630
1
-74.91%
$858,762.00

HCWB Institutional Investors: Active Positions

Increased Positions4+33.33%18,587+15.22%
Decreased Positions4-33.33%49,166-40.25%
New Positions2New14,239New
Sold Out Positions<1Sold Out<1Sold Out
Total Postitions120%91,582-25.03%

HCWB Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Drw Securities, Llc$93.002.78%83,436+83,436New2025-09-30
Vanguard Group Inc$17.000.51%15,426+15,426New2025-09-30
Geode Capital Management, Llc$12.000.37%11,001+11,001New2025-09-30
Golden State Wealth Management, Llc$11.000.33%10,00000%2025-09-30
Wells Fargo & Company/Mn$2.000.06%1,70000%2025-09-30
Tower Research Capital Llc (Trc)$2.000.05%1,562+1,312+524.8%2025-09-30
Citigroup Inc$00.01%311+311New2025-09-30
Osaic Holdings, Inc.$0<0.01%2600%2025-09-30
Bank Of America Corp /De/$00%1000%2025-09-30
Sbi Securities Co., Ltd.$00%1-5-83.33%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

No data is available at this moment.
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.